Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1030 | Control Wiki | 0.28 |
| drug2981 | Placebo oral tablet Wiki | 0.18 |
| drug421 | Azithromycin Wiki | 0.16 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of our prospective monocentric, randomized, controlled trial is to evaluate the effects of intravenous lidocaine on gas exchange and inflammation in acute respiratory distress syndrome (ARDS) due or not to Covid-19 pneumonia. Half of the patients will receive intravenous lidocaine and the other half will receive intravenous NaCl 0,9 % as placebo.
Description: PaO2/FiO2 ratio
Measure: alveolar-capillary gas exchange after two days of treatment Time: At 48 hours after the first treatment administrationDescription: PaO2/FiO2 ratio : a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: alveolar-capillary gas exchange From day 0 to day 21 or until coming out of intensive care Time: From day 0 to day 21 or until coming out of intensive careDescription: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Ventilator-free days Time: At day 28 and at day 90Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Measure the effects of Intravenous Lidocaine on Biomarkers : Ferritin Time: At Day 0, day 2, day 7, day 14 and at day 21Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Measure the effects of Intravenous Lidocaine on Biomarkers : bicarbonates Time: At Day 0, day 2, day 7, day 14 and at day 21Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Measure the effects of Intravenous Lidocaine on Biomarkers : CRP Time: At Day 0, day 2, day 7, day 14 and at day 21Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Measure the effects of Intravenous Lidocaine on Biomarkers : LDH Time: At Day 0, day 2, day 7, day 14 and at day 21Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Measure the effects of Intravenous Lidocaine on Biomarkers : IL-6 Time: At Day 0, day 2, day 7, day 14 and at day 21Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Measure the effects of Intravenous Lidocaine on Biomarkers : Tropo HS Time: At Day 0, day 2, day 7, day 14 and at day 21Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Measure the effects of Intravenous Lidocaine on Biomarkers : Triglycerides Time: At Day 0, day 2, day 7, day 14 and at day 21Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Measure the effects of Intravenous Lidocaine on Biomarkers : CBC with lymphocytes count Time: At Day 0, day 2, day 7, day 14 and at day 21Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Antithrombotic activity of Intravenous Lidocaine on platelets Time: At Day 0, day 2, day 7, day 14 and at day 21Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Antithrombotic activity of Intravenous Lidocaine on ACT ratio Time: At Day 0, day 2, day 7, day 14 and at day 21Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Antithrombotic activity of Intravenous Lidocaine on fibrinogen Time: At Day 0, day 2, day 7, day 14 and at day 21Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Antithrombotic activity of Intravenous Lidocaine on D-Dimers Time: At Day 0, day 2, day 7, day 14 and at day 21Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Antithrombotic activity of Intravenous Lidocaine on TEG Time: At Day 0, day 2, day 7, day 14 and at day 21Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Antithrombotic activity of Intravenous Lidocaine on thromboembolic events Time: At Day 0, day 2, day 7, day 14 and at day 21Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Plasma concentration of albumin and Lidocaine Time: 4 hours after first administration, at day 2, day 7, day 14 and at day 21Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19. Blood pressure in mmHg will be measured
Measure: Search for hemodynamic dysfynction: Blood pressure measurement in mmHg Time: daily from day one to day 14Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19. Cardiac frequency in beats per minute will be assessed
Measure: Search for hemodynamic dysfynction: Cardiac frequency in beats per minute will be assessed Time: daily from day one to day 14Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19. Sinus rythm will be assessed
Measure: Search for hemodynamic dysfynction: Sinus rythm will be assessed Time: daily from day one to day 14Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19. Vasopressors and inotropes drugs use will be reported
Measure: Search for hemodynamic dysfynction: Vasopressors and inotropes drugs use will be reported Time: daily from day one to day 14Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19. EKG : PR, QRS, QTc intervals in ms will be measured
Measure: Search for hemodynamic dysfynction: EKG : PR, QRS, QTc intervals in ms will be measured Time: daily from day one to day 14Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: ICU ileus: laxation response Time: daily from Day 0 to Day 28Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Opioids, sedative and curare sparing effect (drugs dosage) Time: daily from Day 0 to Day 28Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Evaluate the impact of Lidocaine IV on ICU outcomes : re-intubation Time: From Day0 to Day28 and at Day90Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Evaluate the impact of Lidocaine IV on ICU outcomes : ICU length of stay Time: From Day0 to Day28 and at Day90Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Evaluate the impact of Lidocaine IV on ICU outcomes : ICU complications Time: From Day0 to Day28 and at Day90Description: a comparison will be made between Lidocaine and control groups in patients with acute respiratory distress syndrome (ARDS) due to Covid-19 and in patients with ARDS without Covid-19.
Measure: Cough at extubation time or in the 24 hours after extubation or weaning from respiratory support (in case of tracheostomy) Time: extubation dayAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports